Major Molecular Response

Asciminib as a Robust Treatment Option for BCR::ABL1 T315I-Mutated Chronic Myeloid Leukemia: Final Phase 1 Trial Outcomes

Long-term phase 1 data confirm asciminib’s efficacy and safety in treating CML-CP patients harboring the resistant BCR::ABL1 T315I mutation, with sustained major molecular responses and manageable adverse events over nearly six years.